Skip to main content
Join

New Rapid Molecular Test for Tuberculosis Can Simultaneously Detect Resistance to First- and Second-Line Drugs

News

Abstract
The Foundation for Innovative New Diagnostics (FIND) and Cepheid, Inc, announced today the launch of the new Xpert® MTB/XDR* test, which enables expanded drug-resistance tuberculosis (TB) profiling in less than 90 minutes. Xpert MTB/XDR can be used to empower clinicians to quickly prescribe treatment regimens for extensively drug-resistant TB (XDR-TB).
Visit original source to read more
Key Data
  • Publication Date
    24 July 2020
  • Primary Author
    FIND
  • Source
    PHARMA'S ALMANAC
  • Language
    English
Click below to visit original source:
Read More